Nutanix, Inc. (NTNX)

Theseus Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is August - July.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Apr 30, 2025	Jul 31, 2024	Jul 31, 2023	Jul 31, 2022	Jul 31, 2021	Jul 31, 2020
Cash & Equivalents	872.6	655.27	512.93	402.85	285.72	318.74
Short-Term Investments	1,010	339.07	924.47	921.43	928.01	401.04
Cash & Short-Term Investments	1,882	994.34	1,437	1,324	1,214	719.78
Cash Growth	13.99%	-30.82%	8.54%	9.11%	68.63%	-20.80%
Accounts Receivable	270.23	229.8	157.25	124.56	180.78	242.52
Other Receivables	9.73	8.02	5.95	7.51	8.29	16.94
Receivables	279.97	237.81	163.21	132.07	189.07	259.45
Prepaid Expenses	68.62	62.82	85	48.84	36.46	31.69
Other Current Assets	179.99	186.32	176.14	152.79	123.01	83.1
Total Current Assets	2,411	1,481	1,862	1,658	1,562	1,094
Property, Plant & Equipment	285.91	216.3	196.18	232.18	237.52	270.5
Goodwill	185.24	185.24	184.94	185.26	185.26	185.26
Other Intangible Assets	2.81	34.17	14.13	15.83	32.01	49.39
Long-Term Deferred Charges	180.11	198.96	237.99	252.23	232.49	146.83
Other Long-Term Assets	31.52	27.96	31.94	22.27	27.95	22.54
Total Assets	3,097	2,144	2,527	2,366	2,277	1,769
Accounts Payable	49.6	45.07	29.93	44.93	47.06	54.03
Accrued Expenses	184.38	197.61	145.66	136.14	159.93	95.55
Current Portion of Long-Term Debt	-	-	-	145.46	-	-
Current Portion of Leases	28.76	28.12	33.09	42.49	44.44	36.57
Current Income Taxes Payable	-	1.93	2.19	13.21	13.31	9.7
Current Unearned Revenue	1,009	954.54	823.67	720.99	636.42	534.57
Other Current Liabilities	10.08	17.08	101.59	57.35	26.74	29.78
Total Current Liabilities	1,282	1,244	1,136	1,161	927.89	760.2
Long-Term Debt	1,343	570.07	1,218	1,156	1,056	490.22
Long-Term Leases	124.22	97.03	78.66	97.59	93.13	116.79
Long-Term Unearned Revenue	1,020	918.16	771.37	724.55	676.5	648.87
Other Long-Term Liabilities	39.22	42.46	30.03	27.36	536.33	27.44
Total Liabilities	3,808	2,872	3,234	3,166	3,290	2,044
Common Stock	0.01	0.01	0.01	0.01	0.01	0.01
Additional Paid-In Capital	4,180	4,119	3,931	3,584	2,615	2,245
Retained Earnings	-4,894	-4,847	-4,633	-4,378	-3,627	-2,522
Comprehensive Income & Other	3.39	0.15	-5.17	-6.08	-0.01	2.03
Total Common Equity	-711.43	-728.15	-707.42	-800.5	-1,012	-274.98
Shareholders' Equity	-711.43	-728.15	-707.42	-800.5	-1,012	-274.98
Total Liabilities & Equity	3,097	2,144	2,527	2,366	2,277	1,769
Total Debt	1,496	695.22	1,330	1,442	1,193	643.59
Net Cash (Debt)	386.89	299.13	107.48	-117.46	20.47	76.19
Net Cash Growth	46.03%	178.30%	-	-	-73.14%	-83.06%
Net Cash Per Share	1.37	1.22	0.46	-0.53	0.10	0.39
Filing Date Shares Outstanding	268.08	265.21	239.61	227.03	214.22	201.99
Total Common Shares Outstanding	268.28	265.18	239.61	226.94	214.2	201.95
Working Capital	1,129	236.95	725.63	497.42	634.37	333.82
Book Value Per Share	-2.65	-2.75	-2.95	-3.53	-4.72	-1.36
Tangible Book Value	-899.48	-947.55	-906.49	-1,002	-1,229	-509.63
Tangible Book Value Per Share	-3.35	-3.57	-3.78	-4.41	-5.74	-2.52
Machinery	461.61	437.73	397.27	358.04	317.1	262.27
Leasehold Improvements	68.82	64.61	64.67	61.44	62.68	65.56

Updated May 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q